Small Fiber Neuropathy: Intake Statistics

Ardeshna M1, Patel S1, Denis T2, Vancavage R2, Argoff C3, Feustel P4, De E2

Research Type

Clinical

Abstract Category

Pelvic Pain Syndromes

Abstract 114
Urology 4 - Bladder Pain and Infections
Scientific Podium Short Oral Session 10
Thursday 18th September 2025
16:37 - 16:45
Parallel Hall 2
Pain, Pelvic/Perineal Pelvic Organ Prolapse Questionnaire Sexual Dysfunction Neuropathies: Peripheral
1. Albany Medical College, 2. Department of Urology at Albany Medical Center, 3. Department of Neurology at Albany Medical Center, 4. Department of Neuroscience and Experimental TherapeuticsAlbany Medical College
Presenter
Links

Abstract

Hypothesis / aims of study
Small fiber neuropathy (SFN) affects the unmyelinated Aδ and C fibers, which are responsible for pain transmission and autonomic function. Since, due to the expertise of our collaborating neurologist/pain specialist, our pelvic health center sees a high volume of patients with known SFN, the current study assesses differences in systemic and pelvic symptoms at presentation in patients with a known history of small fiber neuropathy at presentation.
Study design, materials and methods
All patients presenting to our institution’s subspecialty Urogynecology and Reconstructive Pelvic Surgery (URPS) and Multidisciplinary Pelvic Pain Clinics were requested to complete an electronic multidisciplinary intake questionnaire, consisting of history, validated measures, and review of systems (ROS) including neurological and autonomic ROS. Patients reporting a history of SFN had undergone a comprehensive neurological workup with a neurologist subspecialized in pain management, leading to a positive skin biopsy to confirm the diagnosis. Comparisons were made among  those with without SFN in 1) the general subspecialized presenting population 2) those reporting presence of pelvic (bladder, bowel, sexual, pain) symptoms and 3) those reporting pelvic pain.

Statistical analysis included t-tests for continuous variable comparison and chi-squared tests and Fisher's exact tests for categorical variable comparison.
Results
The results are viewable in Table 1, Table 2 and Table 3
Interpretation of results
22 of 600 patients (3.7%) reported a known diagnosis of SFN at presentation. The average age with and without SFN were 46 ± 15 year vs. 54 ± 18 years, respectively.

Patients with SFN had significantly higher POPDI-6 (40.5 ± 12.5 vs. 31.1 ± 19.1, p = 0.014) and GUPIQOL q9 scores (4.82 ± 1.18 vs. 4.25 ± 1.53, p = 0.038) compared to those without. Additionally, patients with SFN reported significantly more neurological symptoms (5.73 ± 3.22 vs. 2.04 ± 2.44, p < 0.001), localized pelvic pain sites (12.41 ± 6.14 vs. 5.59 ± 5.85, p < 0.001), extra-pelvic pain sites (6.91 ± 3.24 vs. 2.25 ± 2.45, p < 0.001), and autonomic symptoms (12.09 ± 5.95 vs. 4.21 ± 4.52, p < 0.001).

Among patients with pelvic symptoms, concurrent presence of SFN was associated with higher POPDI-6  (40.5 ± 12.5 vs. 31.2 ± 19.1, p = 0.014), more autonomic symptoms (12.2 ± 6.1 vs. 4.7 ± 4.8, p = 0.001), and increased neurological symptoms (5.8 ± 3.3 vs. 2.3 ± 2.5, p < 0.001). These patients also had a higher number of localized pelvic pain sites (13.0 ± 5.7 vs. 7.1 ± 5.8, p < 0.001) and extra-pelvic pain sites (6.9 ± 3.3 vs. 2.5 ± 2.6, p < 0.001). Concurrent SFN in patients with pelvic symptoms was associated with lower orgasm intensity (2.0 ± 0.5 vs. 2.5 ± 1.0, p = 0.009).

Among patients with pain, those with SFN exhibited more autonomic (12.5 ± 6.3 vs. 5.9 ± 5.4, p < 0.001) and neurological symptoms (6.1 ± 3.2 vs. 3.1 ± 2.7, p < 0.001) compared to those without. These patients also had a higher number of localized pelvic pain sites (13.7 ± 5.5 vs. 10.9 ± 5.1, p = 0.043) and extra-pelvic pain sites (7.1 ± 3.3 vs. 3.0 ± 2.9, p = 0.001). SFN was associated with lower orgasm intensity (2.0 ± 0.5 vs. 2.4 ± 1.0, p = 0.036).
Concluding message
Small fiber neuropathy is an emerging condition relevant to pelvic health specialists. Symptomatology in those with SFN is more severe, even than those presenting with pelvic symptomatology for subspecialized URPS and Pain Management. SFN also increases symptom burden in patients with existing pelvic symptoms and pelvic pain.
Figure 1 Table 1: Pelvic symptomatology in all patients with small fiber neuropathy (SFN) versus patients without SFN. High significance is denoted by *** (p-value < 0.001), statistical significance is denoted by ** (p-value < 0.01), and marginal significance is d
Figure 2 Table 2: Differences in pelvic symptomatology in patients with pelvic symptoms with and without small fiber neuropathy (SFN) . High significance is denoted by *** (p-value < 0.001), statistical significance is denoted by ** (p-value < 0.01), and marginal
Figure 3 Table 3: Differences in pelvic symptomatology in patients with pelvic pain with and without small fiber neuropathy (SFN). High significance is denoted by *** (p-value < 0.001), statistical significance is denoted by ** (p-value < 0.01), and marginal signi
Disclosures
Funding "Grants: Underactive Bladder (NIDDK) Clinical Research: PI, Ironwood Pharmaceuticals Consultant: Flume catheters, Luca Biologics. Infinite MD/Consumer Medical/Alight Online 2nd Opinion Advisory Board: Ironwood Pharmaceuticals Glycologix Other:National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (NIDDK/NIH) Principal Investigator: Jeffrey M. Lackner, PsyD ClinicalTrials.gov ID: NCT05127616 – Chair, DSMB* Stock: ERYP Doximity Clinical Trial No Subjects None
04/07/2025 14:55:22